VPC
Vestal Point Capital Portfolio holdings
AUM
$1.9B
This Quarter Return
+12.07%
1 Year Return
-12.28%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$1.21B
AUM Growth
+$1.21B
(+28%)
Cap. Flow
+$234M
Cap. Flow
% of AUM
19.34%
Top 10 Holdings %
Top 10 Hldgs %
61.52%
Holding
77
New
29
Increased
16
Reduced
11
Closed
19
Top Buys
| 1 |
Cytokinetics
CYTK
|
$147M |
| 2 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$50.8M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$47.1M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$45.2M |
| 5 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
$38.4M |
Top Sells
| 1 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$58.1M |
| 2 |
Merck
MRK
|
$43.6M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
$38.4M |
| 4 |
Vaxcyte
PCVX
|
$33M |
| 5 |
Pacira BioSciences
PCRX
|
$32.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Cytokinetics
CYTK
$4.23B
| $151M | 12.47% | 2,150,000 +2,100,000 | +4,200% | +$147M |
|
|
2
Jazz Pharmaceuticals
JAZZ
$7.75B
| $132M | 10.95% | 1,100,000 +375,000 | +52% | +$45.2M |
|
3
Neurocrine Biosciences
NBIX
$13.8B
| $97.9M | 8.1% | 710,000 -90,000 | -11% | -$12.4M |
|
4
Ascendis Pharma
ASND
$11.8B
| $79.4M | 6.56% | 525,000 -100,000 | -16% | -$15.1M |
|
5
Globus Medical
GMED
$8.27B
| $53.6M | 4.44% | 1,000,000 +200,000 | +25% | +$10.7M |
|
6
Soleno Therapeutics
SLNO
$3.6B
| $53.5M | 4.42% | 1,250,000 -50,000 | -4% | -$2.14M |
|
|
7
Alnylam Pharmaceuticals
ALNY
$58.5B
| $52.3M | 4.33% | 350,000 +315,000 | +900% | +$47.1M |
|
|
ONC
8
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $50.8M | 4.2% | +325,000 | New | +$50.8M |
|
|
NARI
9
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $38.4M | 3.17% | +800,000 | New | +$38.4M |
|
10
Applied Therapeutics
APLT
$71M
| $34.7M | 2.87% | 5,110,000 +955,000 | +23% | +$6.49M |
|
11
Liquidia Corp
LQDA
$2.38B
| $29.5M | 2.44% | 2,000,000 +975,000 | +95% | +$14.4M |
|
12
ALX Oncology
ALXO
$62.7M
| $29.1M | 2.41% | 2,610,000 +955,000 | +58% | +$10.6M |
|
13
AstraZeneca
AZN
$248B
| $27.1M | 2.24% | 400,000 +150,000 | +60% | +$10.2M |
|
14
uniQure
QURE
$896M
| $24.6M | 2.03% | 4,725,000 +800,000 | +20% | +$4.16M |
|
15
Insmed
INSM
$28.8B
| $20.3M | 1.68% | 750,000 -150,000 | -17% | -$4.07M |
|
16
argenx
ARGX
$43.6B
| $19.7M | 1.63% | +50,000 | New | +$19.7M |
|
17
Xenon Pharmaceuticals
XENE
$2.98B
| $17.2M | 1.42% | 400,000 +225,000 | +129% | +$9.69M |
|
18
TG Therapeutics
TGTX
$4.65B
| $16M | 1.32% | +1,050,000 | New | +$16M |
|
19
Astria Therapeutics
ATXS
$349M
| $15.5M | 1.28% | +1,100,000 | New | +$15.5M |
|
20
BioMarin Pharmaceuticals
BMRN
$11.2B
| $15.3M | 1.26% | +175,000 | New | +$15.3M |
|
|
ALPN
21
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $13.9M | 1.15% | +350,000 | New | +$13.9M |
|
22
Solid Biosciences
SLDB
$427M
| $13.8M | 1.14% | 1,035,000 +1,000,915 | +2,937% | +$13.3M |
|
23
Dianthus Therapeutics
DNTH
$759M
| $13.7M | 1.13% | 455,000 +320,000 | +237% | +$9.6M |
|
24
Apellis Pharmaceuticals
APLS
$3.48B
| $13.2M | 1.09% | +225,000 | New | +$13.2M |
|
25
Sarepta Therapeutics
SRPT
$1.78B
| $12.9M | 1.07% | +100,000 | New | +$12.9M |
|